Autopsy report · NCT02730871
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
Cause of deathSlow enrollment
“Enrollment Challenges”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 1 month before it stopped.
- 173 participants enrolled.
- Results were posted on the registry 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Alcon Research
- Sponsor type
- Industry
- Conditions
- Open-angle Glaucoma; Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide/brimonidine vehicle; Travoprost 0.004%/timolol 0.5% solution
- Participants
- 173
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
“Major challenge for enrollment of participants.” - Early Childhood Obesity Among Rural Residents of West Texas
“Enrollment issues” - Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
“Enrollment challenges, study not feasible” - Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
“Difficulties of enrollment” - Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)
“Difficult enrollment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.